ConductScience.org, home

Gene · 6571

SLC18A2: solute carrier family 18 member A2

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. SLC18A2: solute carrier family 18 member A2. Genes, record 6571. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6571

On this page

Gene

Symbol
SLC18A2
HGNC
Name
solute carrier family 18 member A2
HGNC
NCBI Gene ID
6571
NCBI Gene
HGNC ID
HGNC:10935
HGNC
Ensembl
ENSG00000165646
NCBI Gene
Aliases
PKDYS2, SVAT, SVMT, VAT2, VMAT2
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q05940Synaptic vesicular amine transporter51432Ensembl, GeneID, HGNC

Source UniProt

Patents37

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4770680 A12026-07-0816Q05940Espacenet
JP 2026004568 A2026-01-1464098Q05940Espacenet
EP 4641202 A22025-10-291392Q05940Espacenet
JP 2025529142 A2025-09-044033Q05940Espacenet
JP 2025118609 A2025-08-134Q05940Espacenet
US 12371689 B22025-07-294033Q05940Espacenet
WO 2025036766 A12025-02-202Q05940Espacenet
EP 4506468 A12025-02-122Q05940Espacenet
KR 1020250017231 A2025-02-041392Q05940Espacenet
US 12083116 B22024-09-105Q05940Espacenet

1 to 10 of 37

See all 37 patents

Drugs15

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
BENZPHETAMINECHEMBL3545985Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
BENZPHETAMINE HYDROCHLORIDECHEMBL3544906Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DESERPIDINECHEMBL1200515Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DEUTETRABENAZINECHEMBL3137326Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DEXTROAMPHETAMINECHEMBL612Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DEXTROAMPHETAMINE ADIPATECHEMBL1200782Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DEXTROAMPHETAMINE SACCHARATECHEMBL3989844Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
DEXTROAMPHETAMINE SULFATECHEMBL3544971Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
LISDEXAMFETAMINECHEMBL1201222Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL
LISDEXAMFETAMINE DIMESYLATECHEMBL1201178Synaptic vesicular amine transporter inhibitorINHIBITORChEMBL

1 to 10 of 15

See all 15 drugs

Trials173

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07601516DEUTETRABENAZINEPHASE4ClinicalTrials.gov
NCT07111988VALBENAZINEPHASE2ClinicalTrials.gov
NCT06967857DEXTROAMPHETAMINE SULFATEPHASE2ClinicalTrials.gov
NCT06847399LISDEXAMFETAMINE DIMESYLATEPHASE2ClinicalTrials.gov
NCT06771323VALBENAZINEPHASE2ClinicalTrials.gov
NCT06312189VALBENAZINEPHASE3ClinicalTrials.gov
NCT05957055LISDEXAMFETAMINEPHASE2ClinicalTrials.gov
NCT05790239DEXTROAMPHETAMINEPHASE2ClinicalTrials.gov
NCT05654870VALBENAZINEPHASE3ClinicalTrials.gov
NCT05621174DEXTROAMPHETAMINEClinicalTrials.gov

1 to 10 of 173

See all 173 trials

NIH grants2,143

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleSLC18A2 papersNewest fiscal year
T32ES012870Graduate and Postdoctoral Training in Environmental Health Science and Toxicology322025
P30ES019776HERCULES: Exposome Research Center222025
R01ES023839Vesicular modulation of dopamine neuron toxicity142025
ZIANS003034Biomarkers of Catecholaminergic Neurodegeneration142025
R01DA007418The Dopamine Synapse and Associative Learning112025
ZIAMH002386Chemical Coding of Neurotransmission92025
R01ES010563Mechanisms of Manganese Neurotoxicity72025
UL1TR001863Yale Clinical and Translational Science Award62025
ZIADA000522Preclinical medication development for stimulant use disorder62025
P30ES005022Rutgers Center for Environmental Exposure and Disease (CEED)52025

1 to 10 of 2,143Source NIH's project files

See all 2,143 nih grants

Papers3,040

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Identification of a shared blood-brain transcriptomic signature in Parkinson's disease using bioinformatic and network pharmacology approaches.Neuroscience202642826760PubTator, text miningPubMed
Molecular mechanisms of Microcystin-LR decreasing dopamine release by binding VPS35 and clinical correlation between Microcystin-LR exposure and Parkinson's disease.J Environ Sci (China)202642822928PubTator, text miningPubMed
Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis.Neurotox Res202642821203PubTator, text miningPubMed
The mechanism underlying tardive dyskinesia: an exploratory test of the dopamine overactivity hypothesis using MRI imaging of midbrain neuromelanin.Psychopharmacology (Berl)202642809103PubTator, text miningPubMed
Stereoselectivity of pleiotropic monoamine transporter 2-benzoylpiperidine inhibitors and their potential application as novel pharmacological tools.Biochem Pharmacol202642800567PubTator, text miningPubMed
Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel)202642797415PubTator, text miningPubMed
A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia.Clin Case Rep202642750933PubTator, text miningPubMed
Neuromodulation therapies in the management of tardive dyskinesia: A scoping review.Indian J Psychiatry202642725344PubTator, text miningPubMed
Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions.Metab Brain Dis202642714656PubTator, text miningPubMed
Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes.J Cent Nerv Syst Dis202642682903PubTator, text miningPubMed

1 to 10 of 3,040

See all 3,040 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6571

GET https://conductscience.org/api/genes/v1/6571/patents?page=2